Abstract
Small interfering RNAs (siRNA) have a broad potential as therapeutic agents to reversibly silence any target gene of interest. The clinical application of siRNA requires the use of safe and effective delivery systems. In this study, we investigated the use of nonionic surfactant vesicles (NISV) for the delivery of siRNA. Different types of NISV formulations were synthesized by microfluidic mixing and then evaluated for their physiochemical properties and cytotoxicity. The ability of the NISV to carry and transfect siRNA targeting green fluorescent protein (GFP) into A549 that stably express GFP (copGFP-A549) was evaluated. Flow cytometry and Western blotting were used to study the GFP expression knockdown, and significant knockdown was observed as a result of siRNA delivery to the cells by NISV. This occurred in particular when using Tween 85, which was able to achieve more than 70% GFP knockdown. NISV were thus demonstrated to provide a promising and effective platform for therapeutic delivery of siRNA.
| Language | English |
|---|---|
| Pages | 2450-2458 |
| Number of pages | 9 |
| Journal | Molecular Pharmaceutics |
| Volume | 14 |
| Issue number | 7 |
| Early online date | 1 Jun 2017 |
| DOIs | |
| Publication status | Published - 3 Jul 2017 |
Fingerprint
Keywords
- drug delivery
- microfluidics
- nonionic surfactant vesicles
- RNA interference
Cite this
}
Formulation of Nonionic Surfactant Vesicles (NISV) prepared by microfluidics for therapeutic delivery of siRNA into cancer cells. / Obeid, Mohammad A.; Elburi, Ashref; Young, Louise C.; Mullen, Alexander B.; Tate, Rothwelle J.; Ferro, Valerie A.
In: Molecular Pharmaceutics, Vol. 14, No. 7, 03.07.2017, p. 2450-2458.Research output: Contribution to journal › Article
TY - JOUR
T1 - Formulation of Nonionic Surfactant Vesicles (NISV) prepared by microfluidics for therapeutic delivery of siRNA into cancer cells
AU - Obeid, Mohammad A.
AU - Elburi, Ashref
AU - Young, Louise C.
AU - Mullen, Alexander B.
AU - Tate, Rothwelle J.
AU - Ferro, Valerie A.
PY - 2017/7/3
Y1 - 2017/7/3
N2 - Small interfering RNAs (siRNA) have a broad potential as therapeutic agents to reversibly silence any target gene of interest. The clinical application of siRNA requires the use of safe and effective delivery systems. In this study, we investigated the use of nonionic surfactant vesicles (NISV) for the delivery of siRNA. Different types of NISV formulations were synthesized by microfluidic mixing and then evaluated for their physiochemical properties and cytotoxicity. The ability of the NISV to carry and transfect siRNA targeting green fluorescent protein (GFP) into A549 that stably express GFP (copGFP-A549) was evaluated. Flow cytometry and Western blotting were used to study the GFP expression knockdown, and significant knockdown was observed as a result of siRNA delivery to the cells by NISV. This occurred in particular when using Tween 85, which was able to achieve more than 70% GFP knockdown. NISV were thus demonstrated to provide a promising and effective platform for therapeutic delivery of siRNA.
AB - Small interfering RNAs (siRNA) have a broad potential as therapeutic agents to reversibly silence any target gene of interest. The clinical application of siRNA requires the use of safe and effective delivery systems. In this study, we investigated the use of nonionic surfactant vesicles (NISV) for the delivery of siRNA. Different types of NISV formulations were synthesized by microfluidic mixing and then evaluated for their physiochemical properties and cytotoxicity. The ability of the NISV to carry and transfect siRNA targeting green fluorescent protein (GFP) into A549 that stably express GFP (copGFP-A549) was evaluated. Flow cytometry and Western blotting were used to study the GFP expression knockdown, and significant knockdown was observed as a result of siRNA delivery to the cells by NISV. This occurred in particular when using Tween 85, which was able to achieve more than 70% GFP knockdown. NISV were thus demonstrated to provide a promising and effective platform for therapeutic delivery of siRNA.
KW - drug delivery
KW - microfluidics
KW - nonionic surfactant vesicles
KW - RNA interference
UR - http://www.scopus.com/inward/record.url?scp=85021701734&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.7b00352
DO - 10.1021/acs.molpharmaceut.7b00352
M3 - Article
VL - 14
SP - 2450
EP - 2458
JO - Molecular Pharmaceutics
T2 - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
SN - 1543-8384
IS - 7
ER -